The FDA approved Cobenfy, a new treatment for schizophrenia, in 2024. Bristol Myers Squibb CEO described it as effective with fewer side effects than existing medications. Patients and doctors have given positive feedback, suggesting potential for broader applications beyond schizophrenia.